NCD Epidemiology Research Center, Shiga University of Medical Science.
Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
J Atheroscler Thromb. 2022 Sep 1;29(9):1359-1371. doi: 10.5551/jat.63030. Epub 2021 Oct 22.
The roles of urinary albumin, eGFRcystatin (eGFRcys), and eGFRcreatinine (eGFRcre) in the progression of coronary artery calcification (CAC) remain unclear. Therefore, the present study investigated the relationship between kidney function and CAC progression.
A total of 760 Japanese men aged 40-79 years were enrolled in this population-based study. Kidney function was measured using eGFRcre, eGFRcys, and the urine albumin-to-creatinine ratio. CAC scores were calculated using the Agatston method. CAC progression was defined as an annual increase of >10 Agatston units (AU) among men with 0<CAC<100 AU at baseline, that of >10% among those with CAC ≥ 100 AU, and any progression for those with CAC=0 at baseline. The relative risk (RR) of CAC progression based on kidney function was assessed using a robust Poisson regression model.
The mean follow-up period was 4.9 years. CAC progression was detected in 45.8% of participants. Positive associations between CAC progression and albuminuria (>30mg/g) (RR: 1.29; 1.09 to 1.53; p=0.004) and low eGFRcys (<60ml/min/1.73m) (RR: 1.27; 1.05 to 1.53; p=0.012) remained significant after adjustments for age, the follow-up time, and computerized tomography type. Following further adjustments for hypertension, diabetes mellitus, dyslipidemia, C-reactive protein, and lifestyle factors, CAC progression was associated with albuminuria (RR: 1.20; 1.01 to 1.43; p=0.04) and low eGFRcys (RR: 1.19; 0.99 to 1.43; p=0.066), but not with eGFRcre.
CAC progression was associated with albuminuria; however, its relationship with eGFRcys was weakened by adjustments for risk factors.
尿白蛋白、eGFR 胱抑素(eGFRcys)和 eGFR 肌酐(eGFRcre)在冠状动脉钙化(CAC)进展中的作用尚不清楚。因此,本研究旨在探讨肾功能与 CAC 进展之间的关系。
本研究共纳入了 760 名年龄在 40-79 岁之间的日本男性。采用 eGFRcre、eGFRcys 和尿白蛋白/肌酐比值来评估肾功能。CAC 评分采用 Agatston 评分法计算。CAC 进展定义为基线 CAC 为 0<CAC<100 AU 的男性中,每年增加>10 AU;基线 CAC≥100 AU 的男性中,每年增加>10%;基线 CAC=0 的男性中,任何 CAC 进展。采用稳健泊松回归模型评估基于肾功能的 CAC 进展的相对风险(RR)。
平均随访时间为 4.9 年。45.8%的参与者发生 CAC 进展。在校正年龄、随访时间和 CT 类型后,CAC 进展与白蛋白尿(>30mg/g)(RR:1.29;1.09 至 1.53;p=0.004)和低 eGFRcys(<60ml/min/1.73m)(RR:1.27;1.05 至 1.53;p=0.012)之间仍存在显著关联。在校正高血压、糖尿病、血脂异常、C 反应蛋白和生活方式因素后,CAC 进展与白蛋白尿(RR:1.20;1.01 至 1.43;p=0.04)相关,与 eGFRcys 相关(RR:1.19;0.99 至 1.43;p=0.066),但与 eGFRcre 无关。
CAC 进展与白蛋白尿有关;然而,在校正危险因素后,其与 eGFRcys 的关系减弱。